Print

F2G Ltd Appoints John H. Rex to Board of Directors  
2/19/2013 12:36:54 PM

Manchester February 19th 2013 F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Dr. John H. Rex to the Company’s Board as an Independent Director. Dr. Rex is a distinguished research scientist and recognized as an opinion leader in the field of infectious disease therapy and, in particular, for antifungal agents. He has a BA in Biochemistry from Rice University, an MD from Baylor College of Medicine, and is Vice President and Head of Infection, Global Medicines Development, at AstraZeneca.

Prior to joining AstraZeneca in 2003, Dr. Rex was Professor of Medicine at the University of Texas Medical School-Houston. Dr. Rex has been the Industry Representative on the US FDA Anti-Infective Drug Advisory Committee (2007- 2011), is Vice-Chair of the Consensus Committee on Microbiology for the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS), is a Highlights Advisor for Nature Reviews Microbiology, is a member of the Wellcome Trust Seeding Drug Discovery Committee, serves on several editorial boards, was formerly an Editor for Antimicrobial Agents and Chemotherapy, and is an Emeritus Editor for www.doctorfungus.org, a non-profit web site devoted to dissemination of information about medical mycology.

Dr. Richard White, Executive Chairman of F2G, commented, “We are delighted to have John join the board and look forward to benefiting from the breadth and depth of his knowledge and experience in the antifungal arena”.

Dr. Rex will become a key member of the Board’s Science Committee, chaired by Dr. Raj Parekh, who remarked “John’s counsel will be critical in helping F2G successfully develop its totally novel class of drugs to treat Aspergillosis – a potentially life-threatening infection usually affecting the lungs.”

Dr. Rex, who will continue his role at AstraZeneca, added, “This is an exciting time to be involved with F2G and participate in bringing a new class of antifungal agents into clinical practice. Aspergillosis remains a serious disease in an era of increasing resistance with few treatment options. In addition, I view this opportunity to work with F2G as a chance to collaborate and bring insights from the biotechnology sector into the anti-infective development work at AstraZeneca.”

About F2G Ltd: Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life- threatening systemic fungal infections in at-risk patient populations. This is a growing health risk for which there are currently limited treatment options and for which demand is increasing globally Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma. For more information visit www.f2g.com


//-->